Scholarlink

<p>The mortality rates have been increasing for glioma in adolescents and young adults (AYAs, aged 15–39 years). However, current biomarkers for clinical assessment in AYAs glioma are limited, prompting the urgent need for identifying ideal prognostic signature. Extracellular matrix is involved in the development of tumors, while their prognostic significance in AYAs glioma remains unclear. By an integrated machine learning workflow and circuit training and validation procedure, we developed a machine learning-derived prognostic signature (MLDPS) based on 1,026 extracellular matrix-related genes and 3 AYAs glioma cohorts. MLDPS exhibited robust and consistent predictive performance in overall survival and could serve as an independent prognostic factor for AYAs glioma. Simultaneously, MLDPS outperformed previous 89 published prognostic signatures and traditional clinical characteristics, confirming the robust predictive capability. Besides, MLDPS had the potential to stratify prognosis in patients with other cancer types. In addition, the tumor microenvironment between high and low MLDPS groups displayed different patterns while more tumor-infiltrating immune cells were observed in high MLDPS group. Additionally, patients in low MLDPS group had significantly prolonged survival when received immunotherapy in cancers including glioblastoma, urothelial carcinoma and melanoma. Overall, our study proposes a promising signature, which can be utilized for clinicians to evaluate prognosis and might provide individualized clinical management for AYAs glioma.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Machine learning derived development and validation of extracellular matrix related signature for predicting prognosis in adolescents and young adults glioma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月7日

查看全文
  • Pancheng Wu,
  • Yi Zheng,
  • Wei Wu,
  • Beichen Zhang,
  • Yichang Wang,
  • Mingjing Zhou,
  • Ziyi Liu,
  • Zhao Wang,
  • Maode Wang,
  • Jia Wang

摘要

The mortality rates have been increasing for glioma in adolescents and young adults (AYAs, aged 15–39 years). However, current biomarkers for clinical assessment in AYAs glioma are limited, prompting the urgent need for identifying ideal prognostic signature. Extracellular matrix is involved in the development of tumors, while their prognostic significance in AYAs glioma remains unclear. By an integrated machine learning workflow and circuit training and validation procedure, we developed a machine learning-derived prognostic signature (MLDPS) based on 1,026 extracellular matrix-related genes and 3 AYAs glioma cohorts. MLDPS exhibited robust and consistent predictive performance in overall survival and could serve as an independent prognostic factor for AYAs glioma. Simultaneously, MLDPS outperformed previous 89 published prognostic signatures and traditional clinical characteristics, confirming the robust predictive capability. Besides, MLDPS had the potential to stratify prognosis in patients with other cancer types. In addition, the tumor microenvironment between high and low MLDPS groups displayed different patterns while more tumor-infiltrating immune cells were observed in high MLDPS group. Additionally, patients in low MLDPS group had significantly prolonged survival when received immunotherapy in cancers including glioblastoma, urothelial carcinoma and melanoma. Overall, our study proposes a promising signature, which can be utilized for clinicians to evaluate prognosis and might provide individualized clinical management for AYAs glioma.